09.12.2016 23:22:00
|
Nevro Announces Filing of Lawsuit by Boston Scientific
REDWOOD CITY, Calif., Dec. 9, 2016 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that Boston Scientific (NYSE:BSX) has filed a lawsuit for patent infringement. The lawsuit, filed in the United States District Court for the District of Delaware, alleges that Nevro is infringing Boston Scientific's patents covering technology related to stimulation leads, batteries, and telemetry units.
Previously, on November 28, 2016, Nevro had filed a patent lawsuit against Boston Scientific asserting Boston Scientific infringes Nevro's patents covering its groundbreaking Senza® system and HF10™ therapy.
About Nevro
Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza system is the only SCS system that delivers Nevro's proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro.
Investor Relations Contact:
Nevro Investor Relations
Katherine Bock
(650) 433-3247
ir@nevro.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nevro-announces-filing-of-lawsuit-by-boston-scientific-300376193.html
SOURCE Nevro Corp.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Nevro Corpmehr Nachrichten
10.11.24 |
Ausblick: Nevro öffnet die Bücher zum abgelaufenen Quartal (finanzen.net) | |
27.10.24 |
Erste Schätzungen: Nevro stellt das Zahlenwerk zum vergangenen Quartal vor (finanzen.net) | |
05.08.24 |
Ausblick: Nevro gibt Ergebnis zum abgelaufenen Quartal bekannt (finanzen.net) | |
22.07.24 |
Erste Schätzungen: Nevro präsentiert Quartalsergebnisse (finanzen.net) |